EMA's Medical Literature Monitoring Service Creates New Complexities For Pharma
This article was originally published in SRA
Executive Summary
Several drug companies are struggling to align their processes with the European Medicines Agency's new medical literature monitoring (MLM) service that was launched earlier this year to reduce the administrative burden associated with monitoring and reporting of suspected adverse reactions from drugs containing certain active substances1,2.
You may also be interested in...
Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.
EMA Tackles Complexities Introduced By Literature Monitoring Service
The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.